| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
For the Quarter Ended December 31, 2025 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
215,084 |
|
$ |
81,180 |
|
$ |
296,264 |
Intersegment |
|
|
|
|
|
|
|
(387) |
Consolidated net sales |
|
|
|
|
|
|
$ |
295,877 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
57,030 |
|
|
36,471 |
|
|
|
Selling, general and administrative |
|
58,993 |
|
|
27,597 |
|
|
|
Research and development |
|
14,446 |
|
|
8,680 |
|
|
|
Segment operating income |
$ |
84,615 |
|
$ |
8,432 |
|
$ |
93,047 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(15,379) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(2,093) |
Certain litigation charges |
|
|
|
|
|
|
|
(2,140) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(14,198) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(3,739) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(1,037) |
Consolidated operating income |
|
|
|
|
|
|
$ |
54,461 |
|
|
|
|
|
|
|
|
|
For the Quarter Ended December 31, 2024 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
211,551 |
|
$ |
84,135 |
|
$ |
295,686 |
Other revenue(1) |
|
|
|
|
|
|
|
1,849 |
Intersegment |
|
|
|
|
|
|
|
(504) |
Consolidated net sales |
|
|
|
|
|
|
$ |
297,031 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
51,927 |
|
|
35,595 |
|
|
|
Selling, general and administrative |
|
57,483 |
|
|
35,064 |
|
|
|
Research and development |
|
15,029 |
|
|
10,236 |
|
|
|
Segment operating income |
$ |
87,112 |
|
$ |
3,240 |
|
$ |
90,352 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(18,559) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(2,195) |
Certain litigation charges |
|
|
|
|
|
|
|
(1,386) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(15,238) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(3,287) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(1,641) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(627) |
Consolidated operating income |
|
|
|
|
|
|
$ |
47,419 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.
|
|
|
|
|
|
|
|
|
For the Six Months Ended December 31, 2025 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
417,272 |
|
$ |
160,638 |
|
$ |
577,910 |
Other revenue |
|
|
|
|
|
|
|
5,439 |
Intersegment |
|
|
|
|
|
|
|
(917) |
Consolidated net sales |
|
|
|
|
|
|
$ |
582,432 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
107,547 |
|
|
70,208 |
|
|
|
Selling, general and administrative |
|
118,759 |
|
|
55,448 |
|
|
|
Research and development |
|
28,638 |
|
|
17,672 |
|
|
|
Segment operating income |
$ |
162,328 |
|
$ |
17,310 |
|
$ |
179,638 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(30,729) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(5,444) |
Certain litigation charges |
|
|
|
|
|
|
|
(4,549) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(26,294) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(11,249) |
Recovery of assets held-for-sale |
|
|
|
|
|
|
|
6,789 |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(3,470) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(2,573) |
Consolidated operating income |
|
|
|
|
|
|
$ |
102,119 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since June 30, 2025.
|
|
|
|
|
|
|
|
|
For the Six Months Ended December 31, 2024 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
416,086 |
|
$ |
167,327 |
|
$ |
583,413 |
Other revenue(1) |
|
|
|
|
|
|
|
4,152 |
Intersegment |
|
|
|
|
|
|
|
(1,076) |
Consolidated net sales |
|
|
|
|
|
|
$ |
586,489 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
104,425 |
|
|
71,228 |
|
|
|
Selling, general and administrative |
|
114,616 |
|
|
68,583 |
|
|
|
Research and development |
|
29,392 |
|
|
20,000 |
|
|
|
Segment operating income |
$ |
167,653 |
|
$ |
7,517 |
|
$ |
175,170 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(38,300) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(3,896) |
Certain litigation charges |
|
|
|
|
|
|
|
(1,678) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(25,875) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(14,309) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(3,227) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(479) |
Consolidated operating income |
|
|
|
|
|
|
$ |
87,406 |
(1) Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.
|